Expert Opinion on Investigational Drugs
- Print ISSN
- Electronic ISSN
- Impact factor
- Usage rank
- Article count
- Free count
- Free percentage
- PDFs via platforms
- CSA, Proquest, Ingenta, Informaworld, Rcgp, and Informahealthcare
Na+ H+ exchanger-1: a link with atherogenesis?
We herein review the contribution of NHE-1 in atherogenesis (namely its effect on endothelial cells, monocytes, smooth muscle cells and platelets). What the reader will gain: Studies have shown that NHE is involved in atherogenesis-related properties of isolated monocytes. We also consider the relat...
New small molecules for the treatment of Parkinson's disease.
We will describe how development programs of novel molecules now additionally consider non-motor features of PD as promising targets in order to obtain regulatory approval. Regulatory authorities increasingly exert influence on trial designs, demanding therapeutic effects that are not always clinica...
Evolution of endocrine adjuvant therapy for early breast cancer.
We need the results from ongoing studies to decide what may be the optimal duration of therapy and regimen (sequential treatment versus monotherapy; one drug compared with another). Further, there is a need to critically assess optimal use of endocrine therapy for metastatic disease among patients p...
Evolving pathway-driven biomarkers in breast cancer.
We briefly review the following pathways from the perspective of biomarkers through works from Dr Kumar's lab: i) estrogen receptor alpha (ER) signaling; ii) nuclear receptor coregulators in ER-directed therapies; iii) p21-activated kinase-1 in ER action; iv) cytoskeleton components in breast cancer...
Sustained-release naltrexone: novel treatment for opioid dependence.
The devastating costs of opioid abuse and dependence underscore the need for effective treatments for these disorders. At present, several different maintenance medications exist for treating opioid dependence, including methadone, buprenorphine and naltrexone. Of these, naltrexone is the only one t...
Recent advances in the development of telomerase inhibitors for the treatment of cancer.
We review recent advances in the development of telomerase inhibitors for the treatment of cancer. To date, these have included antisense strategies, reverse transcriptase inhibitors and compounds capable of interacting with high-order telomeric DNA tetraplex ('G-quadruplex') structures to prevent e...
DNA vaccines for cancer therapy.
Vaccination with a tumour antigen-expressing plasmid DNA (pDNA) is a novel approach to human cancer immunotherapy. Initial results in preclinical rodent tumour models are promising, revealing that pDNA cancer vaccines can elicit both humoral, as well as cell-mediated immunity and, in...
Endothelin receptor antagonists: novel agents for the treatment of hypertension?
We now possess direct evidence that such drugs are effective as antihypertensives in some experimental models of hypertension. Furthermore, the ability of ET-receptor antagonists to prevent hypertension-induced end-organ damage is also well documented. Their capacity to reverse already established t...
Rosiglitazone: a new therapy for Type 2 diabetes.
Rosiglitazone (Avandiatrade mark) is a new generation thiazolidinedione used in the treatment of Type 2 diabetes. As with other thiazolidinediones, it binds to the gamma-isoform of the peroxisome proliferator-activated receptor (PPAR), a nuclear hormone receptor. Subsequent to PPAR-g...
Recent advances in transgenic model development for Alzheimer's disease.
The lack of a small animal model that represents major features of Alzheimer's disease has long been considered a major handicap for research and drug development. Transgenic technology has been used to introduce potential pathological start points as well as established genetic causes of the diseas...